argenx Stock (NASDAQ:ARGX), Trade Ideas

argenx

Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was approved in the U.S. in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022.

pharma lab worker ai

Analyst Color

Biotech

Equities

News

Health Care

Price Target

Initiation

Analyst Ratings

Trading Ideas

General

ARGX

RNAC

Cartesian Therapeutics&#39; autoimmune disease treatment with re-dosable mRNA CAR-Ts. Learn about Descartes-08, a promising anti-BCMA CAR-T therapy offering deeper, longer-lasting efficacy than current standards. Analysts project substantial market capture and peak sales potential.

Cartesian Therapeutics&#39; Rare Disease Candidate Shows Long Lasting Benefit Over Argenx&#39;s Vyvgart, Analyst Initiates With Buy

Small Cap

Markets

AXSM

MSFT

STOK

TSLA

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Tesla To $120? Here Are 10 Top Analyst Forecasts For Tuesday

Penny Stocks

Intraday Update

Movers

ABTS

ALAB

AMTX

APYX

ASST

AVGR

BPTS

CRML

CURI

CZOO

DRCT

FIVE

GOEV

HOUS

INTJ

JOAN

KAVL

LVWR

LXEH

MVLA

NSYS

OCGN

OTRK

PALT

PGEN

PRTG

PYXS

SPIR

STEM

TITN

TRML

WLDS

YTEN

Shares of  FactSet Research Systems Inc. (NYSE: FDS) fell sharply during Thursday’s session after the company reported worse-than-expected second-quarter revenue and issued FY24 guidance.

Why FactSet Research Shares Are Trading Lower By Around 5%? Here Are Other Stocks Moving In Thursday&#39;s Mid-Day Session

argenx SE

Morgan Stanley analyst Ravi Shanker maintains Union Pacific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNP#NYSE">UNP</a>) with a Equal-Weight and raises the price target from $198 to $210.

Morgan Stanley Maintains Equal-Weight on Union Pacific, Raises Price Target to $210

Morgan Stanley analyst Simeon Gutman maintains Tractor Supply (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSCO#NASDAQ">TSCO</a>) with a Underweight and raises the price target from $195 to $235.

TSCO

Morgan Stanley Maintains Underweight on Tractor Supply, Raises Price Target to $235

TD Cowen analyst Andrew Charles reiterates Chipotle Mexican Grill (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMG#NYSE">CMG</a>) with a Buy and maintains $3500 price target.

Reiteration

TD Cowen Reiterates Buy on Chipotle Mexican Grill, Maintains $3500 Price Target

Morgan Stanley analyst Brian Nowak maintains Snap (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNAP#NYSE">SNAP</a>) with a Underweight and raises the price target from $11 to $12.

SNAP

Morgan Stanley Maintains Underweight on Snap, Raises Price Target to $12

Morgan Stanley analyst Toni Kaplan maintains Rollins (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ROL#NYSE">ROL</a>) with a Equal-Weight and raises the price target from $42 to $43.

Morgan Stanley Maintains Equal-Weight on Rollins, Raises Price Target to $43

Renowned entrepreneur and real estate mogul Grant Cardone accused the government of pilfering people's hard-earned money in a post on social media platform X, where he highlighted the contentious issue of wealth redistribution and governmental fiscal policies.
Cardone's April 25<a href="https://twitter.com/GrantCardone/status/1783534196839031162"> post on X</a> outlined how the government "steals" your money by taking 40% of your earnings; taxing you between 8% and 12% on the purchases you make; imposing a 20% corporate tax for starting a business; and — for the few estates larger than $13.61 million per individual or a combined $27.22 million for a married couple — charging an inheritance tax when you die.
But Cardone said he offers a solution through his real estate investment firm Cardone Capital. For example, if you invest $1 million for 10 years, you would have cash flow of $800,000 and a profit assumption of $1 million for a total return of $2.8 million and depreciation of $500,000.
Don't Miss:
<ul>
<li>Investing in real estate just got a whole lot simpler. This <a href="https://www.benzinga.com/go/bezos-landlord">Jeff Bezos-backed startup will allow you to become a landlord</a> in just 10 minutes, and you only need $100.</li>
<li>Want To Grow Your Wealth Passively? Unlock Real Wealth with <a href="https://www.benzinga.com/money/cityfunds-yield">Cityfunds&#8217; Exclusive 8% Yield Fund</a>.</li>
</ul>
Cardone, author of the recently released book<a href="https://store.grantcardone.com/products/the-wealth-creation-formula-book"> "The Wealth Creation Formula,"</a> said professional real estate investors can use the $500,000 depreciation to reduce tax on earned income from other businesses or can exchange the entire gain and buy another asset.
That would give you a $1.8 million asset that pays your estate $108,000 per year or $9,000 per month in passive income.
"Most of this is not taxed in the first four or five years as you achieve another $900,000 in depreciation to offset taxes from [the] new purchase," Cardone posted. "This is why so many rich people invest in real estate."
Trending:
<ul>
<li>Elon Musk Is Bullish On Austin. Here&#8217;s <a href="https://www.benzinga.com/go/musk-austin">How To Invest In The City&#8217;s Growth Before He Floods It With New Tech Workers</a>.</li>
</ul>
Despite encouraging professional real estate investors to purchase properties, Cardone has said<a href="https://www.benzinga.com/general/24/04/38186250/grant-cardone-lists-beachfront-mansion-he-bought-from-tommy-hilfiger-priced-at-646-bitcoin"> that homeownership is a trap</a> because you are physically stuck in the same place and that renting is a better choice because it provides flexibility.
"The house, for most people, is a nightmare — not a dream," he said.
Cardone has been an outspoken critic of the Biden administration's fiscal policies. In an April 24 post on X, he wrote, "Joe Biden just stated, ‘We are investing in Ukraine, in Europe — $905,000,000,000 and won't take one question. Where is the investment in America?"
And on April 22, he wrote, "Can someone tell me, why we are sending ANOTHER $100B we don't have to Ukraine?"
Read Next:
<ul>
<li>Dara Khosrowshahi-Backed Startup Lets You <a href="https://www.benzinga.com/go/dara-backed-startup">Become a Landlord with $100</a>.</li>
<li>Miami Is Expected To Take New York's Place As The US Financial Capital. <a href="https://www.benzinga.com/go/miami-financial-capital">Invest In It With $500 Before That Happens</a>.</li>
</ul>

Real Estate

Grant Cardone Sounds Off: Government Guilty Of Pocketing People's Hard-Earned Cash

Morgan Stanley analyst Joseph Moore maintains KLA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLAC#NASDAQ">KLAC</a>) with a Equal-Weight and raises the price target from $692 to $698.

KLAC

Morgan Stanley Maintains Equal-Weight on KLA, Raises Price Target to $698

Small Cap Consumer Research analyst Eric Beder reiterates Betterware de Mexico SAPI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BWMX#NASDAQ">BWMX</a>) with a Buy and maintains $22.5 price target.

BWMX

Small Cap Consumer Research Reiterates Buy on Betterware de Mexico SAPI, Maintains $22.5 Price Target

Altria Group Inc&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MO#NYSE">MO</a>), maker of Marlboro, reportedly urged the U.S. Food and Drug Administration to combat illegal vape products, citing threat to public health.
Chief Executive Officer Billy Gifford criticized the FDA&#8217;s enforcement scale and scope, according to a&nbsp;<a target="_blank" href="https://www.bloomberg.com/news/articles/2024-04-25/illegal-vapes-rising-altria-mo-asks-fda-for-more-enforcement?srnd=industries-v2&amp;sref=TBDibEcD" rel="noreferrer noopener">report&nbsp;</a>from Bloomberg.
Gifford emphasized the need for&nbsp;stronger&nbsp;FDA crackdown on&nbsp;<a target="_blank" href="https://www.benzinga.com/markets/cannabis/23/07/33259407/war-on-vapes-intensifies-fda-seizes-disposable-vapes-nyc-files-lawsuit-uk-calls-for-ban-on-singl" rel="noreferrer noopener">unauthorized e-cigarettes.</a>
NJOY e-cigarette&#8217;s retail share improved, with plans to expand to 100,000 stores by year-end.
Altria reported a first-quarter FY24 sales decline of 2.5% year-on-year to $5.58 billion, beating the analyst&#8217;s consensus estimate of $4.71 billion. Adjusted EPS of $1.15&nbsp;<a target="_blank" href="https://www.benzinga.com/news/earnings/24/04/38429242/altrias-marlboro-shipment-volume-plunges-8-7-in-q1-whats-going-on" rel="noreferrer noopener">was in line with the consensus estimate</a>.
Retail&nbsp;share of&nbsp;NJOY&nbsp;in the U.S. multi-outlet and convenience channel was 4.3%, an&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/04/b38426149/altria-reports-2024-first-quarter-results-reaffirms-full-year-guidance" rel="noreferrer noopener">increase of 0.6 share points sequentially.</a>
The reported shipment volume of&nbsp;NJOY&nbsp;consumables was approximately 10.9 million units in the first quarter.
&#8220;In spite of&nbsp;the absence of an effective regulatory environment, we saw continued early momentum from NJOY and believe our businesses are on track to deliver against full-year plans,&#8221; said CEO Billy Gifford.
Altria acquired&nbsp;<a target="_blank" href="https://www.benzinga.com/m-a/23/03/31214690/altria-scoops-e-cigarette-maker-njoy-holdings-for-2-75b-cash" rel="noreferrer noopener">NJOY Holdings&nbsp;Inc</a><a target="_blank" href="https://www.benzinga.com/m-a/23/03/31214690/altria-scoops-e-cigarette-maker-njoy-holdings-for-2-75b-cash" rel="noreferrer noopener">&nbsp;in 2023 for $2.75 billion</a>.
Altria stock lost over 6% in the last 12 months. Investors can gain exposure to the stock via&nbsp;Vanguard Total Stock Market ETF&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTI#NYSE">VTI</a>) and&nbsp;IShares Core High Dividend ETF&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HDV#NYSE">HDV</a>).
Price Action: MO shares are trading higher by 0.10% at $43.59&nbsp;at the last check Friday.
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Image Via Shutterstock

Media

Altria CEO Urges FDA Crackdown On Illicit Vape Products: Report

Snap Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNAP#NYSE">SNAP</a>) shares were climbing Friday after the company <a href="https://www.benzinga.com/markets/equities/24/04/38456421/snap-gains-over-25-whats-going-on">reported higher-than-expected earnings for its first quarter</a>.
The results came amid an <a href="https://www.benzinga.com/calendars/earnings">exciting earnings season</a>. Here are some key analyst takeaways from the release.
<h1 class="wp-block-heading">Goldman Sachs On Snap</h1>
Analyst Eric Sheridan reiterated a Neutral rating while raising the price target from $13.50 to $16.
Snap reported strong first-quarter revenue growth of 21% year-on-year, beating Street expectations, "driven by both direct response (+17% YoY driven by improvements to the ad platform) and brand (+12% YoY)," Sheridan wrote in a note. 
He added that the company's adjusted EBITDA of $46 million was "meaningfully higher" than guidance.
Total DAU (daily active user) growth remained robust in the quarter, with net additions of more than 8 million, the analyst stated. The company also guided to DAU net adds of 9 million for the second quarter, he further said.
<h1 class="wp-block-heading">Raymond James On Snap</h1>
Analyst Josh Beck maintained an Outperform rating while lifting the price target from $15 to $16.
Snap recorded revenues of $1.195 billion, representing 21% growth, which surpassed consensus, while also guiding to higher-than-expected growth of 15% to 18% year-on-year for the second quarter, Beck said. 
The company attributed the slowdown in revenue growth to "tougher comps y/y and up to 3pts of seasonality impact from Ramadan and leap day in 1Q24," he added.
"Significant platform highlights included Snapchat+ subscribers 3x y/y beyond 9M subscribers and spotlight time spent +125% y/y," the analyst further stated.
Check out <a href="https://www.benzinga.com/analyst-stock-ratings">other analyst stock ratings</a>.
<h1 class="wp-block-heading">Morgan Stanley On Snap</h1>
Analyst Brian Nowak reaffirmed an Underweight rating while raising the price target from $11 to $12.
Snap's higher-than-expected revenue growth was driven by "growth across both direct response and brand ads," while advertisers saw a 75% improvement in purchase conversions, Nowak said.
The company's results highlight "solid execution to start the year with improved traction amongst SMB advertisers," the analyst wrote. 
The "strong adoption of conversion API product Engagement remains critical," as the company aims to reengage more high-monetizing users in North America and "drive personalization through better content ranking models," he added.
<h1 class="wp-block-heading">JPMorgan On Snap</h1>
Analyst Doug Anmuth reiterated an Underweight rating while lifting the price target from $11 to $13.
While Snap's results indicated broad-based strength, which drove revenue upside, growth is expected to decelerate, Anmuth said in a note.
"Overall, the macro backdrop stabilized, while enhancements to the ad stack drove increased spending," the analyst wrote. He added, however, that Snap's results "have historically been choppy and we are hesitant to extrapolate from one-quarter of strong results."
<h1 class="wp-block-heading">Oppenheimer On Snap</h1>
Analyst Jason Helfstein maintained a Perform rating on the stock.
Snap reported revenues 7% higher than Street estimates, on higher-than-expected ARPDU (average revenue per daily user), Helfstein said. "While two-year accelerated 500bps vs. 4Q to +7%, SNAP guided 2Q +6%, suggesting lack of confidence following 1Q performance," he added.
"Furthermore, engagement remains weak, with NA/EU flat sequentially, as all growth continues to be in ROW which has weaker monetization," the analyst wrote.
<h1 class="wp-block-heading">Roth MKM On Snap</h1>
Analyst Rohit Kulkarni reiterated a Neutral rating, while revising the price target to $15.
"Snap&#8217;s clean beat 1Q results and upbeat 2Q guide reinforced our near-term thinking, as we held an incremental positive bias heading into earnings," Kulkarni wrote in a note. 
"Snap&#8217;s progress in attracting SMB advertisers and growing its DR business deserves applause, and recent macro recovery in brand-related ad spend seems to be benefiting Snap," he added.
The analyst stated, however, that the company's AI infrastructure investments continue to be elevated, impacting operating and gross margins.
<h1 class="wp-block-heading">Piper Sandler On Snap</h1>
Analyst Thomas Champion maintained a Neutral rating and price target of $15.
"Re-working the DR product is having an impact and perhaps most impressive, active SMB advertisers were +85% y/y," Champion said.
"All-in, a better 1Q, but 2Q revenue guide was in-line with our forecast and SNAP remains the most expensive name in social," he added.
<h1 class="wp-block-heading">BMO Capital Markets On Snap</h1>
Analyst Brian Pitz reaffirmed an Outperform rating and price target of $20.
"Green shoots of a positive ad inflection are here, with ad revenue growth accelerating to 15.7% from 1.8% in 4Q23, the fastest growth rate since 1Q22," Pitz said. He added, however, that the company is yet to benefit from growth in North America.
"Engagement should rise for lapsed users while organic growth should gain momentum," the analyst wrote. 
He further stated that Snap could grow advertising revenues by double digits to mid-teens in 2024 and beyond.
<h1 class="wp-block-heading">Benchmark On Snap</h1>
Analyst Mark Zgutowicz reiterated a Hold rating on the stock.
"We were encouraged with SNAP's SMB customer progression in 1Q, reported up +85% y/y," Zgutowicz wrote in a note.
"While this number is a bit ambiguous without an understanding of its SMB base and average revenue, it may suggest SNAP's several SMB revenue partnerships are starting to bear fruit," he added.
<h1 class="wp-block-heading">JMP Securities On Snap</h1>
Analyst Andrew Boone maintained a Market Perform rating on the stock.
Snap's second-quarter guidance implies a sequential deceleration due to tougher comps and seasonality factors, which could prove to be "conservative," Boone said.
"While we are incrementally positive after Snap's results, comps are likely to become tougher in 2H24 as Snap laps the growth of Snapchat+ and results have historically been volatile as we await greater consistency," he added.
SNAP Price Action: Shares of Snap had risen by 27.72% to $14.56 at the time of publication on Friday.
Read Next: <a href="http://Dan Ives Says AI Is The 'Fourth Industrial Revolution' After 'Robust' Results From Microsoft And Google: '1995 Moment'">Dan Ives Says AI Is The &#8216;Fourth Industrial Revolution&#8217; After &#8216;Robust&#8217; Results From Microsoft And Google: &#8216;1995 Moment&#8217;</a>
Photo: Shutterstock

Earnings

Earnings Misses

Social Media

Snap Investors Celebrate Q1 Earnings, But Analysts Aren't Ready To Party Just Yet: 'The Most Expensive Name In Social'

Deep-pocketed investors have adopted a bearish approach towards Tenet Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in THC usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 12 extraordinary options activities for Tenet Healthcare. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 33% leaning bullish and 58% bearish. Among these notable options, 2 are puts, totaling $133,288, and 10 are calls, amounting to $579,946.
<h3>Predicted Price Range</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $92.5 to $97.5 for Tenet Healthcare over the recent three months. 
<h3>Volume &amp; Open Interest Trends</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Tenet Healthcare's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Tenet Healthcare's whale trades within a strike price range from $92.5 to $97.5 in the last 30 days. 
<h3>Tenet Healthcare 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1714149959_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>THC</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/17/24</td>
<td>$6.0</td>
<td>$5.8</td>
<td>$6.0</td>
<td>$92.50</td>
<td>$139.2K</td>
<td>49</td>
<td style="text-align: right;">784</td>
</tr>
<tr>
<td>THC</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/17/24</td>
<td>$3.5</td>
<td>$3.3</td>
<td>$3.3</td>
<td>$92.50</td>
<td>$98.6K</td>
<td>1.0K</td>
<td style="text-align: right;">102</td>
</tr>
<tr>
<td>THC</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/17/24</td>
<td>$5.0</td>
<td>$4.9</td>
<td>$5.0</td>
<td>$92.50</td>
<td>$90.7K</td>
<td>49</td>
<td style="text-align: right;">201</td>
</tr>
<tr>
<td>THC</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/17/24</td>
<td>$6.2</td>
<td>$6.0</td>
<td>$6.0</td>
<td>$92.50</td>
<td>$72.6K</td>
<td>49</td>
<td style="text-align: right;">785</td>
</tr>
<tr>
<td>THC</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>05/17/24</td>
<td>$6.1</td>
<td>$5.9</td>
<td>$5.9</td>
<td>$92.50</td>
<td>$59.0K</td>
<td>49</td>
<td style="text-align: right;">402</td>
</tr>
</tbody>
</table>

<h3>About Tenet Healthcare</h3>
Tenet Healthcare is a Dallas-based healthcare services organization. It operates a collection of hospitals (about 60 as of December 2023) and over 450 ambulatory surgery centers and other outpatient facilities across the U.S., primarily in the South. Through its Conifer segment, Tenet also provides revenue cycle management solutions.
Following our analysis of the options activities associated with Tenet Healthcare, we pivot to a closer look at the company's own performance.
<h3>Where Is Tenet Healthcare Standing Right Now?</h3>
<ul>
<li>Currently trading with a volume of 681,347, the THC's price is down by -1.89%, now at $95.67. </li>
<li>RSI readings suggest the stock is currently may be approaching oversold.</li>
<li>Anticipated earnings release is in 4 days.</li>
</ul>
<h3>What The Experts Say On Tenet Healthcare</h3>
3 market experts have recently issued ratings for this stock, with a consensus target price of $115.0.
<ul>
<li>An analyst from Cantor Fitzgerald downgraded its action to Overweight with a price target of $104. </li>
<li>Maintaining their stance, an analyst from Deutsche Bank continues to hold a Buy rating for Tenet Healthcare, targeting a price of $126. </li>
<li>An analyst from Wells Fargo has decided to maintain their Overweight rating on Tenet Healthcare, which currently sits at a price target of $115. </li>
</ul>
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Tenet Healthcare options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Options

Check Out What Whales Are Doing With THC

Deep-pocketed investors have adopted a bearish approach towards Thermo Fisher Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in TMO usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 8 extraordinary options activities for Thermo Fisher Scientific. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 25% leaning bullish and 50% bearish. Among these notable options, 3 are puts, totaling $378,172, and 5 are calls, amounting to $204,826.
<h3>Predicted Price Range</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $570.0 to $680.0 for Thermo Fisher Scientific over the last 3 months. 
<h3>Volume &amp; Open Interest Development</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Thermo Fisher Scientific's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Thermo Fisher Scientific's whale activity within a strike price range from $570.0 to $680.0 in the last 30 days. 
<h3>Thermo Fisher Scientific Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1714149948_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th style="text-align: right;">Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>TMO</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$49.5</td>
<td>$48.0</td>
<td>$49.5</td>
<td>$600.00</td>
<td>$257.4K</td>
<td style="text-align: right;">195</td>
<td style="text-align: right;">52</td>
</tr>
<tr>
<td>TMO</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>05/10/24</td>
<td>$8.3</td>
<td>$8.2</td>
<td>$8.2</td>
<td>$572.50</td>
<td>$83.7K</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>TMO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$58.2</td>
<td>$56.1</td>
<td>$58.2</td>
<td>$570.00</td>
<td>$58.2K</td>
<td style="text-align: right;">196</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>TMO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/20/24</td>
<td>$4.9</td>
<td>$4.7</td>
<td>$4.7</td>
<td>$680.00</td>
<td>$47.9K</td>
<td style="text-align: right;">22</td>
<td style="text-align: right;">1</td>
</tr>
<tr>
<td>TMO</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>05/17/24</td>
<td>$11.6</td>
<td>$8.2</td>
<td>$9.25</td>
<td>$570.00</td>
<td>$37.0K</td>
<td style="text-align: right;">208</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>

<h3>About Thermo Fisher Scientific</h3>
Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of mid-2023 (revenue figures include some cross-segment revenue): analytical technologies (16% of sales); specialty diagnostic products (10%); life science solutions (24%); and lab products and services, which includes CRO services (54%).
After a thorough review of the options trading surrounding Thermo Fisher Scientific, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Present Market Standing of Thermo Fisher Scientific</h3>
<ul>
<li>With a trading volume of 530,072, the price of TMO is up by 0.18%, reaching $572.76.</li>
<li>Current RSI values indicate that the stock is is currently neutral between overbought and oversold.</li>
<li>Next earnings report is scheduled for 89 days from now.</li>
</ul>
<h3>Professional Analyst Ratings for Thermo Fisher Scientific</h3>
Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $629.0.
<ul>
<li>An analyst from Goldman Sachs persists with their Buy rating on Thermo Fisher Scientific, maintaining a target price of $640. </li>
<li>Maintaining their stance, an analyst from HSBC continues to hold a Buy rating for Thermo Fisher Scientific, targeting a price of $660. </li>
<li>An analyst from Deutsche Bank has decided to maintain their Buy rating on Thermo Fisher Scientific, which currently sits at a price target of $610. </li>
<li>Consistent in their evaluation, an analyst from Baird keeps a Outperform rating on Thermo Fisher Scientific with a target price of $620. </li>
<li>An analyst from Barclays has decided to maintain their Equal-Weight rating on Thermo Fisher Scientific, which currently sits at a price target of $615. </li>
</ul>
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Thermo Fisher Scientific options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Spotlight on Thermo Fisher Scientific: Analyzing the Surge in Options Activity

Morgan Stanley analyst Erik Woodring maintains IBM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBM#NYSE">IBM</a>) with a Equal-Weight and lowers the price target from $186 to $179.

Morgan Stanley Maintains Equal-Weight on IBM, Lowers Price Target to $179

Deep-pocketed investors have adopted a bearish approach towards Affirm Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFRM#NASDAQ">AFRM</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in AFRM usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 16 extraordinary options activities for Affirm Holdings. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 25% leaning bullish and 68% bearish. Among these notable options, 10 are puts, totaling $667,512, and 6 are calls, amounting to $331,690.
<h3>Projected Price Targets</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $20.0 to $55.0 for Affirm Holdings over the last 3 months. 
<h3>Volume &amp; Open Interest Development</h3>
In terms of liquidity and interest, the mean open interest for Affirm Holdings options trades today is 1133.47 with a total volume of 3,998.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Affirm Holdings's big money trades within a strike price range of $20.0 to $55.0 over the last 30 days.
<h3>Affirm Holdings Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1714149943_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>AFRM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/17/24</td>
<td>$4.5</td>
<td>$4.2</td>
<td>$4.35</td>
<td>$35.00</td>
<td>$172.2K</td>
<td>2.5K</td>
<td style="text-align: right;">423</td>
</tr>
<tr>
<td>AFRM</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$7.2</td>
<td>$7.05</td>
<td>$7.15</td>
<td>$30.00</td>
<td>$143.0K</td>
<td>1.4K</td>
<td style="text-align: right;">1</td>
</tr>
<tr>
<td>AFRM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/03/24</td>
<td>$1.24</td>
<td>$1.21</td>
<td>$1.21</td>
<td>$33.00</td>
<td>$89.8K</td>
<td>433</td>
<td style="text-align: right;">15</td>
</tr>
<tr>
<td>AFRM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/21/24</td>
<td>$4.1</td>
<td>$4.05</td>
<td>$4.1</td>
<td>$32.50</td>
<td>$61.9K</td>
<td>2.4K</td>
<td style="text-align: right;">32</td>
</tr>
<tr>
<td>AFRM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/03/24</td>
<td>$1.02</td>
<td>$1.01</td>
<td>$1.01</td>
<td>$32.00</td>
<td>$58.8K</td>
<td>500</td>
<td style="text-align: right;">64</td>
</tr>
</tbody>
</table>

<h3>About Affirm Holdings</h3>
Affirm Holdings Inc offers a platform for digital and mobile-first commerce. It comprises a point-of-sale payment solution for consumers, merchant commerce solutions, and a consumer-focused app. The firm generates its revenue from merchant networks, and through virtual card networks among others. Geographically, it generates a majority share of its revenue from the United States.
<h3>Affirm Holdings's Current Market Status</h3>
<ul>
<li>Currently trading with a volume of 3,127,376, the AFRM's price is up by 5.09%, now at $33.26. </li>
<li>RSI readings suggest the stock is currently is currently neutral between overbought and oversold.</li>
<li>Anticipated earnings release is in 12 days.</li>
</ul>
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Affirm Holdings options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

AFRM

This Is What Whales Are Betting On Affirm Holdings

MF International Shares Resume Trade, Stock Now Down -75%

Morgan Stanley analyst Michael Phillips maintains Hartford Finl Servs Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIG#NYSE">HIG</a>) with a Equal-Weight and lowers the price target from $110 to $109.

Morgan Stanley Maintains Equal-Weight on Hartford Finl Servs Gr, Lowers Price Target to $109

In Queens, New York, a homeowner's confrontation with unexpected occupants at her late father's house spiraled into a dramatic legal tangle that highlights the complex issue of squatter rights in the city.
Adele Andaloro, 47, inherited a property valued at $1 million after her parents died. She discovered strangers living there during a visit to prepare the house for sale. When she changed the locks to secure the property, one of the occupants called the police, leading to her brief arrest. Though she faces no charges, the ordeal showcases the difficulties homeowners and law enforcement face with squatters in New York.
According to the Daily Mail, Andaloro voiced her concerns about the effectiveness of local laws, stating, "I'm really fearful that these people are going to get away with stealing my home."
Don't Miss:
<ul>
<li>Investing in real estate just got a whole lot simpler. This <a href="https://www.benzinga.com/go/bezos-landlord">Jeff Bezos-backed startup will allow you to become a landlord</a> in just 10 minutes, and you only need $100.</li>
<li>Want To Grow Your Wealth Passively? Unlock Real Wealth with <a href="https://www.benzinga.com/money/cityfunds-yield">Cityfunds&#8217; Exclusive 8% Yield Fund</a>.</li>
</ul>
Neighbors have reported suspicious activity since the occupants moved in.&nbsp;
"We all know what they are up to, so we're all kind of pissed about it," Kosta, a 24-year-old college student living next door, told the news outlet.&nbsp;
Squatter's rights in New York offer a legal framework that can make eviction challenging. After 30 days of occupancy in New York City, squatters can claim legal rights to a property, complicating efforts to remove them. This situation has left Andaloro and her neighbors frustrated as they navigate the legal and social implications of squatter claims.
The incident has sparked a broader discussion on the need for clearer regulations and more support for property owners facing similar predicaments.
Read Next:
<ul>
<li>Dara Khosrowshahi-Backed Startup Lets You <a href="https://www.benzinga.com/go/dara-backed-startup">Become a Landlord with $100</a>.</li>
<li>Elon Musk Is Bullish On Austin. Here&#8217;s <a href="https://www.benzinga.com/go/musk-austin">How To Invest In The City&#8217;s Growth Before He Floods It With New Tech Workers</a>.</li>
</ul>

A New York Homeowner Was Arrested For Changing The Locks After Finding A Group Of Squatters In $1 Million Home She Inherited

Morgan Stanley analyst Adam Jonas maintains Harley-Davidson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HOG#NYSE">HOG</a>) with a Overweight and raises the price target from $50 to $51.

Morgan Stanley Maintains Overweight on Harley-Davidson, Raises Price Target to $51

Morgan Stanley analyst Matthew Harrison maintains Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) with a Equal-Weight and lowers the price target from $80 to $78.

GILD

Morgan Stanley Maintains Equal-Weight on Gilead Sciences, Lowers Price Target to $78

In a report released today, Tazeen Ahmad from Bank of America Securities maintained a Buy rating on Argenx Se (ARGX – Research Report). The company...

Argenx Se (ARGX) Receives a Buy from Bank of America Securities

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Argenx Se (ARGX – Research Report), Neogen (NEOG –...

Analysts' Opinions Are Mixed on These Healthcare Stocks: Argenx Se (ARGX), Neogen (NEOG) and Supernus Pharmaceuticals (SUPN)

Argenx (ARGX) has released an update. Argenx has announced promising data from the ADHERE trial for its drug VYVGART Hytrulo, potentially offering ...

Argenx's VYVGART Shows Promising CIDP Treatment Results

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on IGM Biosciences (IGMS – Research Report) and Argen...

Analysts' Opinions Are Mixed on These Healthcare Stocks: IGM Biosciences (IGMS) and Argenx Se (ARGX)

William Blair analyst Myles Minter has maintained their neutral stance on ARGX stock, giving a Hold rating on April 3. Myles Minter has given his H...

Maintaining the Edge: Argenx's Hold Rating Amidst Rising Competition and Promising Therapy Results

Jefferies urges deeper dive into mid-caps, picks 12 ideas including GTA-publisher Take-Two

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Elevance Health (ELV – Research Report), Argenx Se (...

Analysts' Top Healthcare Picks: Elevance Health (ELV), Argenx Se (ARGX)

Baron Health Care Fund Q1 2024 Shareholder Letter

Artisan International Fund Q1 2024 Commentary

Piper Sandler analyst Allison Bratzel maintained a Buy rating on Argenx Se (ARGX – Research Report) today and set a price target of $522.00. The co...